Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.
about
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsFavourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursBevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinomaPhase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumoursBevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT studyMultiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review.The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.Metronomic therapy concepts in the management of adrenocortical carcinoma.Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.Inhibition of mTOR in carcinoid tumors.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Metronomic chemotherapy.A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Response assessment in metronomic chemotherapy: RECIST or PERCIST?Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?Neuroendocrine tumors of the thymus: the oncologist point of view.Chemotherapy in NETs: When and how.Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
P2860
Q26996521-C68A12B7-C0CE-44FD-9B8A-1A9D42004F6CQ28247667-12F2BF3B-366A-45F6-BD44-2C74A6BB3271Q31170918-55E7D6F3-14F7-45F5-9C4B-0F9CFC0C9326Q34173001-1BF3AED3-F3F7-4373-93B9-0915354F2AA3Q34248487-4C89FD35-459F-4AFF-9937-BBF338188CC7Q34484273-533D86BF-AAB9-489E-B2F0-3B4C0CF60089Q34746009-3A3DFE39-168D-48C6-B72A-7A41B5854DC8Q35120723-FEFDEBBC-5EED-49BF-B8BD-225107CA9BBFQ35178055-EEA8A5CB-4AD1-40B6-B5A3-85FD387E0C8FQ37846130-7D3E7A45-D6D3-4778-89AB-6772DA776141Q37942484-C458514E-F309-4781-9D28-74820455516FQ38014495-75F19E0D-BEF8-48F5-ACCF-728768CAC12FQ38034141-47E741B4-7FD2-4409-94E8-058E1D26852AQ38087885-2280A73A-DE9E-47D9-9515-87E4F91ACB79Q38248269-47249A3E-FCCC-40B5-9A0D-7113C185CB38Q38249998-AA0383DF-BB1B-4BB3-A5DB-02F341234CFBQ38916996-021611E4-F697-4462-9CC7-892FA5B43FECQ44670305-4B0FB09B-8457-462B-A62F-4F845FA100B7Q45264084-2655E891-F6C8-4BF7-8AA3-C5994302E9C6Q47692261-7AD2F133-256A-435F-A08D-2978C9E36BDDQ47944297-8ECEB865-7B1A-4A18-A30E-A316957D1F1EQ48152898-5F23FE10-AD1A-426E-8A53-9DAE38611369Q51479301-D5D15BB9-8170-4265-BD10-ABC976F74D4DQ56373623-1FC7D538-26B4-4FB6-BE53-7DA0E39BDE05
P2860
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@ast
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@en
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@nl
type
label
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@ast
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@en
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@nl
prefLabel
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@ast
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@en
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@nl
P2093
P2860
P356
P1433
P1476
Continuous 5-fluorouracil infu ...... the Piemonte oncology network.
@en
P2093
Alfredo Berruti
Anna Ferrero
Benedetta Ferretti
Davide Perroni
Enrica Milanesi
Federico Castiglione
Libero Ciuffreda
Luigi Dogliotti
Marco Volante
Maria P Brizzi
P2860
P2888
P356
10.1186/1471-2407-9-388
P407
P577
2009-11-03T00:00:00Z
P5875
P6179
1046698135